Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453502 | 0.95 | TP53 (0.70) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL13470243 | 0.94 | TP53 (0.73) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL13469840 | 0.93 | TP53 (0.67) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL13453512 | 0.93 | TP53 (0.67) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL13469947 | 0.92 | TP53 (0.84) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL13453494 | 0.91 | KMT2A (0.70) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL17066587 | 0.91 | TP53 (0.69) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL17066492 | 0.89 | TP53 (0.76) | TP53KMT2AMEN1GAAALOX12 | |
| SCHEMBL13469959 | 0.88 | KMT2A (0.84) | KMT2AMEN1GAAALOX12ALDH1A1 | |
| SCHEMBL13453486 | 0.88 | KMT2A (0.64) | TP53KMT2AMEN1GAAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126938-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | PCTP, LCAT, CETP | TP53 4776/4885KMT2A 1676/4885MEN1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.